Treatment options for chronic cholestasis in infancy and childhood

Current Treatment Options in Gastroenterology

Volumn 8, Issue 5, 2005, Pages 419-430

  Ng, Vicky Lee ^b   Balistreri, William F ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTACID AGENT; ANTIHISTAMINIC AGENT; BETA CAROTENE; BILE ACID; CALCIUM; CENTRAL DEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; DIPHENHYDRAMINE; ESSENTIAL FATTY ACID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYZINE; MEDIUM CHAIN TRIACYLGLYCEROL; OPIATE RECEPTOR; PHENOBARBITAL; PHOSPHOLIPID; PHOSPHORUS; RETINOL; RETINOL PALMITATE; RIFAMPICIN; TRACE ELEMENT; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN K GROUP; WARFARIN;

ABDOMINAL PAIN; ALPHA TOCOPHEROL DEFICIENCY; ATAXIA; BILE DUCT OBSTRUCTION; BILIOPANCREATIC BYPASS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CALORIC INTAKE; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHILD NUTRITION; CLINICAL FEATURE; COPING BEHAVIOR; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DROWSINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; DYSPEPSIA; EMOTIONAL STRESS; EMOTIONALITY; EXCITEMENT; FAT INTAKE; GENE THERAPY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GRAFT INFECTION; HEMOLYSIS; HEPATOCYTE TRANSPLANTATION; HUMAN; HYPERCALCIURIA; HYPERKALEMIA; HYPOREFLEXIA; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INSOMNIA; INTRAHEPATIC CHOLESTASIS; KIDNEY CALCIFICATION; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MUSCLE WEAKNESS; NEPHROLITHIASIS; NEUROTOXICITY; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; PROTEIN INTAKE; PROTHROMBIN TIME; PRURITUS; RETINOL DEFICIENCY; RETINOL INTOXICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN DISCOLORATION; TASTE DISORDER; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VISUAL IMPAIRMENT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN K DEFICIENCY; XEROSTOMIA;

EID: 28044462679     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0045-5     Document Type: Review

References (49)

1. Bancroft J, Cohen MB: Intracranial hemorrhage due to vitamin K deficiency in breast-fed infants with cholestasis. J Pediatr Gastroenterol Nutr 1993, 16:78-80.
2. Carlton VEH, Knisely AS, Freimer NB: Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic cholestasis region. Hum Mol Genet 1995, 4:1049-1053.
3. Bull LN, van Eijk MJT, Pawlikowska L, et al.: A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998, 18:219-224.
4. Houwen RHJ, Baharloo S, Blankenship K, et al.: Genome screening by searching for shared segments: Mapping a gene for benigh recurrent intrahepatic cholestasis. Nat Genet 1994, 8:380-386.
5. van Mil SW, van der Woerd WL, van der Brugge G, et al.: Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterol 2004, 127:379-384.
6. Strautnieks SS, Bull LN, Knisely AS, et al.: A gene encoding a liver specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998, 20:233-238.
7. Jansen PL, Strautnieks SS, Jacquemin E, et al.: Hepatocanalicular bile salt export protein deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterol 1999, 117:1370-1379.
8. De Vree JML, Jacquemin E, Dubuisson C, et al.: Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996, 23:904-908.
9. Jacquemin E, Setchell KD, O'Connell NC, et al.: A new cause of progressive familial intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr 1994, 125:379-384.
10. Bove KE, Heubi JE, Balistreri WE, et al.: Bile acid synthetic defects and liver disease: A comprehensive review. Pediatr and Devel Path 2004, 7:315-334.
11. Stewart SM, Uauy R, Kennard BD, et al.: Mental development and growth in children with chronic liver disease of early and late onset. Pediatrics 1988, 82:167-172.
12. Stewart S, Uauy R, Waller DA, et al.: Mental and motor development, social competence and growth one year after successful pediatric liver transplantation. J Pediatr 1989, 114:574-581.
13. O'Keefe SJ, El-Zayadi AR, Carraher TE, et al.: Malnutrition and immunocompetence in patients with liver disease. Lancet 1980, 2:615-617.
14. Sokol RJ, Stall C: Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990, 52:203-208.
15. Bucuvalas IC, Cutfield W, Horn H, et al.: Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease. J Pediatr 1990, 117:397-402.
16. Holt RI, Baker AJ, Miell JP: The pathogenesis of growth failure in pediatric liver disease. J Hepatol 1997, 27:413-423.
17. Protheroe SM: Feeding the child with chronic liver disease. Nutrition 1998, 14:796-800.
18. Burke V, Danks DM: Medium chain triglyceride diet: its use in the treatment of liver disease. BMJ 1996, 2:1050-1051.
19. Chin SE, Shepherd RW, Thomas BJ, et al.: Nutritional support in children with end-stage liver disease: a randomized trial of branched-chain amino acid supplement. Am J Clin Nutr 1992, 56:158-163.
20. Bianchi G, Marzocchi R, Agostini F, et al.: Update on branched-chain amino acid supplementation in liver diseases. Curr Opin Gastroenterol 2005, 21:197-200.
21. Socha P, Koletzko B, Swiatkowska E, et al.: Essential fatty acid metabolism in infants with cholestasis. Acta paediatr 1998, 87:278-283.
22. Pettei MJ, Daftary S, Levine JJ: Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease. Am J Clin Nutr 1991, 53:1217-1221.
23. Moreno LA, Gottrand F, Hoden S, et al.: Improvement of nutritional status in cholestatic children with supplemental nocturnal enteral nutrition. J Pediatr Gastroenterol Nutr 1991, 12:213-216.
24. Wayman KI, Cox KL, Esquivel CO: Neurodevelopmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr 1997, 131:894-898.
25. Roberts CC, Book LS, Chan GM, et al.: Rickets in children with cholestatic liver disease: evaluation and treatment. Pediatr Res 1981, 15:544.
26. Sokol RJ: Mechanism causing vitamin E deficiency during chronic childhood cholestasis. Gastroenterology 1983, 85:1172-1182.
27. Sokol RJ: Fat soluble vitamins and their importance in patients with cholestatic liver diseases. Gastroenterol Clin North Am 1994, 23:673-705.
28. Sokol RJ, Butler-Simon N, Conner C, et al.: Multicenter trial of d-alpha-tocopheryl polyethylene Glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastro 1993, 104:1727-1735.
29. Bloomer JR, Boyer JL: Phenobarbital effects in cholestatic liver disease. Ann Intern Med 1975, 82:310-317.
30. Cynamon HA, Andres JM, Iafrate RP: Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterol 1990, 98:1013-1016.
31. Yerushalmi B, Sokol RJ, Narkewicz MR, et al.: Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 1999, 29:442-447.
32. Balistreri WF: Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997, 24:573-589.
33. Balistreri WF, A-Kader HH, Ryckman FC, et al.: Biochemical and clinical response to ursodeoxycholic acid administration in pediatric patients with chronic cholestasis. In Bile Acids as Therapeutic Agents. Edited by Paumgartner G, Stiehl A, Gerok W. Boston: Kluwer Academic; 1991:323-333.
34. Narkewicz MR, Smith D, Gregory C, et al.: Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J Pediatr Gastroenterol Nutr 1998, 26:49-55.
35. Kowdley KV: Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med 2000, 108:481-486.
36. Wolfhagen FH, Sternieri E, Hop WC, et al.: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264-1269.
37. Bergasa NV: Treatment of the pruritus of cholestasis. Curr Treat Options Gastroenterol 2004, 7:501-508.
38. Ng VL, Ryckman FC, Porta G: Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastro Nutr 2000, 30:152-156.
39. Emerick KM, Whitington PF: Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 2002, 35:1501-1506.
40. Kalicinski PJ, Ismail H, Jankowska I, et al.: Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 2003, 13:307-311.
41. Kurbegov AC, Setchell KD, Haas JE, et al.: Biliary diversion for progressive familial intrahepatic cholestasis: Improved liver morphology and bile acid profile. Gastro 2003, 125:1227-1234.
42. Sokol RJ, Heubi JE, Iannaccone ST, et al.: Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N Engl J Med 1984, 310:1209-1212.
43. Argao EA, Heubi JE, Hollis BW, et al.: D-alpha-tocopheryl-polyethylene glycol-1000 succinate enhances the absorption of vitamin D in chronic cholestatic liver disease of infancy and childhood. Pediatr Res 1992, 31:146-150.
44. Sokol RJ, Guggenheim MA, Heubi JE, et al.: Frequency and clinical progression of the vitamin E deficiency neurologic disorder in children with prolonged neonatal cholestasis. Am J Dis Child 1985, 139:1211-1215.
45. Lane PA, Hathaway WE: Vitamin K in infancy. J Pediatr 1985, 106:351-359.
46. Paumgartner G, Beuers U: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
47. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, et al.: Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998, 33:220-224.
48. McDiarmid SV: Current status of liver transplantation in children. Pediatr Clin North Am 2003, 50:1335-1774.
49. McDiarmid SV, Merion RM, Dykstra DM, et al.: Selection of pediatric candidates under the PELD system. Liver Transpl 2004, 10(10 Suppl 2):S23-S30.